Dependency of Tamoxifen Sensitive and Resistant ER⁺ Breast Cancer Cells on Semaphorin 3C (SEMA3C) for Growth.

ABSTRACT: Estrogen receptor positive (ER⁺) breast cancer (BCa) accounts for the highest proportion of breast cancer-related deaths. While endocrine therapy is highly effective for this subpopulation, endocrine resistance remains a major challenge and the identification of novel targets is urgently needed. Previously, we have shown that Semaphorin 3C (SEMA3C) is an autocrine growth factor that drives the growth and treatment resistance of various cancers, but its role in breast cancer progression and endocrine resistance is poorly understood. Here, we report that SEMA3C plays a role in maintaining the growth of ER⁺ BCa cells and is a novel, tractable therapeutic target for the treatment of ER⁺ BCa patients. Analyses of publicly available clinical datasets indicate tha

SUBMITTER: Bhasin S 

PROVIDER: S-EPMC10341167 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature